Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 4, 2010

Ascenta Enters Deal Potentially Worth $398M with Sanofi-Aventis

  • Sanofi-Aventis has obtained an exclusive, worldwide license covering two anticancer agents from Ascenta Therapeutics. The company will pay an up-front fee as well as development, regulatory, and commercial milestones that could reach a total of $398 million.

    The agreement includes two agents that Ascenta in-licensed from the University of Michigan, MI-773 and MI-519-64. These orally active, small molecule candidates inhibit the interaction between HDM2 (human double minute 2) and p53, removing a block to normal p53 tumor suppressor function, and potentially enhancing cancer control and treatment.

    “Restoring tumor suppressor function through the inhibition of the HDM2-p53 interaction offers the potential to control and prevent cancer progression,” says Mel Sorensen, M.D., president and CEO of Ascenta Therapeutics. “Ascenta's mission since its founding has been to discover and develop novel small molecules that can trigger apoptosis in cancer cells.”

    Both companies will continue to fund research on these targets at the University of Michigan, and Ascenta may participate in ongoing research activities and future clinical development. Additionally, Ascenta is eligible to receive tiered royalties on worldwide product sales.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »